We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

87 hedge funds and large institutions have $213M invested in Progenics Pharmaceuticals Inc in 2014 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 30 increasing their positions, 22 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 7

36% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 22

24% more funds holding

Funds holding: 70 → 87 (+17)

4% more call options, than puts

Call options by funds: $1.29M | Put options by funds: $1.24M

15% less capital invested

Capital invested by funds: $251M → $213M (-$37.8M)

Holders
87
Holders Change
+17
Holders Change %
+24.29%
% of All Funds
2.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
30
Reduced
22
Closed
7
Calls
$1.29M
Puts
$1.24M
Net Calls
+$44K
Net Calls Change
+$887K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$8.11M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$5.11M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$3.79M
4
SM
Sabby Management
Florida
+$2.65M
5
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management
California
+$2.59M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.03M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.02M
3
JG
Jefferies Group
New York
-$831K
4
CS
Credit Suisse
Switzerland
-$570K
5
MCM
Moore Capital Management
New York
-$506K
Name Holding Trade Value Shares
Change 		Change in
Stake
BIM
26
BlackRock Investment Management
Delaware
$811K +$138K +26,895 +16%
WAM
27
Wolverine Asset Management
Illinois
$768K +$961K +187,967 New
HCM
28
Highbridge Capital Management
New York
$708K +$885K +172,960 New
AIG
29
American International Group
New York
$639K +$597K +116,743 +295%
TC
30
TFS Capital
Pennsylvania
$610K -$28.4K -5,549 -4%
CS
31
Credit Suisse
Switzerland
$607K -$570K -111,474 -43%
Jacobs Levy Equity Management
32
Jacobs Levy Equity Management
New Jersey
$569K +$711K +139,000 New
Bank of America
33
Bank of America
North Carolina
$554K -$65.7K -12,850 -9%
California State Teachers Retirement System (CalSTRS)
34
California State Teachers Retirement System (CalSTRS)
California
$508K +$83.4K +16,300 +15%
ProShare Advisors
35
ProShare Advisors
Maryland
$498K +$463K +90,492 +290%
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$486K -$271K -52,999 -31%
TA
37
Teachers Advisors
New York
$450K +$163K +31,830 +41%
PPA
38
Parametric Portfolio Associates
Washington
$441K +$259K +50,709 +89%
Charles Schwab
39
Charles Schwab
California
$434K +$108K +21,100 +25%
OAM
40
Oxford Asset Management
United Kingdom
$414K +$518K +101,275 New
GT
41
Glenmede Trust
Pennsylvania
$333K +$241K +47,194 +137%
BCM
42
Bridgeway Capital Management
Texas
$309K +$16K +3,132 +4%
BGA
43
Belmont Global Advisors
Texas
$307K +$384K +75,000 New
MLICM
44
Metropolitan Life Insurance Company (MetLife)
New York
$289K +$32.3K +6,309 +10%
Goldman Sachs
45
Goldman Sachs
New York
$277K -$236K -46,110 -41%
HK
46
Horizon Kinetics
New York
$275K – – –
AQR Capital Management
47
AQR Capital Management
Connecticut
$248K +$16.4K +3,200 +6%
AllianceBernstein
48
AllianceBernstein
Tennessee
$231K +$54.7K +10,700 +23%
Los Angeles Capital Management
49
Los Angeles Capital Management
California
$222K +$277K +54,170 New
NFA
50
Nationwide Fund Advisors
Ohio
$215K +$31.7K +6,201 +13%
1
2
3 4

PGNX Hedge Fund Activity: Q1 2014 in Review

87 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2014, worth a combined $213M — down 15% from $251M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PGNX positions and 7 closed out — a net gain of 17 holders — while 30 added to existing stakes and 22 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $8.11M. The largest seller was Fidelity Investments, cutting an estimated $9.03M.

  • 87 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2014, up from 70 in Q4 2013.
  • Funds reported $213M of Progenics Pharmaceuticals Inc stock for Q1 2014, down 15% quarter-over-quarter.
  • 24 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2014 and 7 closed out, a net change of +17 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q1 2014 was Broadfin Capital, an estimated $8.11M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q1 2014 was Fidelity Investments, an estimated $9.03M sold.

Based on aggregated 13F filings for Q1 2014.